Simplifying Global Compliance
Watson Sues FDA Over Actos Generic Exclusivity as Competitors Launch
Watson Pharmaceuticals is suing the FDA after it failed to grant the company shared exclusivity on a generic of Type 2 diabetes drug Actos.
To View This Article:
Subscribe To Generic Line
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing